Abstract
High-frequency ultrasound (HFUS) is a non-invasive method that detects superficial skin features. Ultra-high frequencies (50-100MHz) can reveal epidermis and dermis structures. In this study, we describe the psoriatic plaque using a new device equipped with a 70MHz probe (VEVO® MD, Fujifilm, VisualSonics) and we assess the lesion before and after ixekizumab. We examined the superficial hyperechoic band, the subepidermal hypoechoic band (SLEB), and the vascularization of the plaque in ten patients affected by plaque psoriasis. The average superficial hyperechoic band thickness was 0.2157mm before treatment, 0.1611mm after 15days, and 0.1354mm (P<.05) after 30days. The SLEB thickness was 0.7535mm at baseline, 0.3300mm after 15days (P<.05), and 0.2007mm (P<.05) after 30days. The average percentage vascularization was 50.21% at baseline, 13.15% after 15days (P<.05), and 5.97% after 30days. UHFUS assessment highlighted the rapid action of the drug in terms of the decrease in vascularization after 15days. It revealed a statistically significant reduction in SLEB thickness after 15days and a significant reduction in the hyperechoic superficial band after 30days. VEVO® MD provides physicians with high-resolution details of the psoriatic plaque, thus enabling tailored-made treatments.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
